title: [Iopamidol, a new non-ionic roentgen contrast medium. Results of angiographic studies in more than 300 patients, with special reference to pain reactions].
abstract: Iopamidol, a new non-ionic, monomeric contrast medium with low osmolality has been well established in our angiographic routine procedures according to the favourable results obtained in more than 300 controlled trials. The general tolerance (demonstrated by the rate of systemic adverse reactions) of the lower concentrated solution (300 mg iodine/ml) is a little bit better than that of the higher concentrated one (370 mg iodine/ml). We could demonstrate a significant difference between the two preparations regarding to local side effects such as pain and heat sensations. The results of 100 intraindividual double blind studies (only peripheral angiography) specially referring to local side effects showed the high significant decrease of pain and heat sensations after application of Iopamidol as compared to the results gained by the ionic Ioxitalamate and Ioglicinate. There was no remarkable difference between Iopamidol and Ioxaglate which is a dimeric but equally low osmolar substance. The role of osmolality in the generation of side effects is pointed out. In consequence the advantages of using contrast media of reduced osmolality particularly in peripheral angiography must be emphasized.
mesh_terms: D000792:Angiography / Q000009:adverse effects; D004311:Double-Blind Method; D004361:Drug Tolerance; D006358:Hot Temperature; D006801:Humans; D007479:Iopamidol; D007483:Iothalamic Acid / Q000009:adverse effects / Q000031:analogs & derivatives*; D007485:Ioxaglic Acid; D009994:Osmolar Concentration; D010146:Pain / Q000209:etiology; D011897:Random Allocation; D014283:Triiodobenzoic Acids
chemical_list: D014283:Triiodobenzoic Acids; D007483:Iothalamic Acid; C002587:ioxitalamic acid; D007479:Iopamidol; D007485:Ioxaglic Acid
vernacular_title: Iopamidol, ein neues, nichtionisches Röntgenkontrastmittel. Ergebnisse angiographischer Untersuchungen bei über 300 Patienten unter besonderer Berücksichtigung von Schmerzreaktionen.